##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Jun 29, 2024

Se Jun Choi  

Abstract

Thyroid function needs to be carefully assessed during the shift from Hashimoto’s to Graves’ disease, using important markers such as thyroid stimulating hormone (TSH) levels, thyroid antibodies, and ultrasound imaging. TSH levels play a crucial role in the diagnosis and treatment of thyroid disorders, since increased levels indicate an underactive thyroid (Hashimoto’s) and decreased levels indicate an overactive thyroid (Graves’). Furthermore, the identification of certain antibodies such as anti-thyroglobulin and anti-thyroperoxidase can aid in distinguishing between the two autoimmune disorders. Ultrasound imaging provides further information by visually representing the dimensions and composition of the thyroid gland, aiding in the early identification of nodules or enlargement linked to both pathological conditions. Consistent surveillance and cooperation among healthcare practitioners are essential for efficiently handling the shift from Hashimoto’s to Graves’ disease, guaranteeing the best possible results for patients.

##plugins.themes.bootstrap3.article.details##

Keywords

Hashimoto’s Thyroiditis, Grave’s Disease, Pathological Shift, Monitor, Diagnosis

References
1. Mincer DL, Jialal I. Hashimoto Thyroiditis. [Updated 2023 Jul 29]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459262/

2. Pokhrel B, Bhusal K. Graves Disease. [Updated 2023 Jun 20]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK448195/

3. Shrestha A, Adhikari N, Devkota S, Chowdhury T, Shiferaw-Deribe Z, Gousy N, Adhikari S. Fluctuating hyperthyroidism and hypothyroidism in Graves’ Disease: The swinging between two clinical entities. Cureus 2022; 14(8):e27715. DOI: https://doi.org/10.7759/cureus.27715

4. Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M. Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, No. 24.) Introduction. Available at: https://www.ncbi.nlm.nih.gov/books/NBK83492/

5. Franco JS, Amaya-Amaya J, Anaya JM. Thyroid disease and autoimmune diseases. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 30. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459466/

6. Franklyn J, Shephard M. Evaluation of Thyroid Function in Health and Disease. [Updated 2000 Sep 21]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK285546/

7. Bishay RH, Chen RC. Hashimoto’s Thyroiditis and Graves’ disease in one patient: The extremes of thyroid dysfunction associated with interferon treatment. Case Rep Endocrinol 2016; 2016:6029415. DOI: https://doi.org/10.1155/2016/6029415

8. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid 2008; 18(9):953-958. DOI: https://doi.org/10.1089/thy.2007.0405

9. Akamizu T, Amino N. Hashimoto’s Thyroiditis. [Updated 2017 Jul 17]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK285557/

10. Alvin Mathew A, Papaly R, Maliakal A, Chandra L, Antony MA. Elevated Graves’ disease-specific thyroid-stimulating immunoglobulin and thyroid stimulating hormone receptor antibody in a patient with subacute thyroiditis. Cureus 2021; 13(11):e19448. DOI: https://doi.org/10.7759/cureus.19448

11. Lee MK, Na DG, Joo L, Lee JY, Ha EJ, Kim JH, Jung SL, Baek JH. Standardized imaging and reporting for thyroid ultrasound: Korean society of thyroid radiology consensus statement and recommendation. Korean J Radiol 2023; 24(1):22-30. DOI: https://doi.org/10.3348/kjr.2022.0894

12. Maia FF, Zantut-Wittmann DE. Thyroid nodule management: Clinical, ultrasound and cytopathological parameters for predicting malignancy. Clinics (Sao Paulo) 2012; 67(8):945-954. DOI: https://doi.org/10.6061/clinics/2012(08)15

13. Yazdaan HE, Jaya F, Sanjna F, Junaid M, Rasool S, Baig A, Natt MZ, Maurya N, Iqbal S, Yeldo BA, Khan AS, Varrassi G, Kumar S, Khatri M, Awan SK. Advances in thyroid function tests: Precision diagnostics and clinical implications. Cureus 2023; 15(11):e48961. DOI: https://doi.org/10.7759/cureus.48961

14. Feldt-Rasmussen U, Klose M. Clinical Strategies in the Testing of Thyroid Function. [Updated 2020 Nov 20]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK285558/

15. Chung J, Lee YJ, Choi YJ, Ha EJ, Suh CH, Choi M, Baek JH, Na DG; Korean Society of Thyroid Radiology (KSThR); Korean Society of Radiology. Clinical applications of Doppler ultrasonography for thyroid disease: Consensus statement by the Korean Society of Thyroid Radiology. Ultrasonography 2020; 39(4):315-330. DOI: https://doi.org/10.14366/usg.20072
How to Cite
Choi, S. J. (2024). Is It Possible to Precisely Monitor Thyroid Function as It Transitions from Hashimoto’s to Grave’s Diseases?. Science Insights, 44(6), 1393–1395. https://doi.org/10.15354/si.24.co195
Section
Commentary